Bluejay Diagnostics, Inc.
BJDXBluejay Diagnostics completes ahead-of-schedule enrollment of 750 patients in pivotal SYMON-II study of Symphony IL-6 sepsis test
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $249.04K | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $199.10K | $780.96K | $200.13K | $145.72K | $157.04K | $142.97K |
| Gross Profit | $-199.10K | $-780.96K | $48.91K | $-145.72K | $-157.04K | $-142.97K |
| Gross Margin | N/A | N/A | 19.64% | N/A | N/A | N/A |
| Operating Expenses | $6.97M | $9.53M | $9.37M | $3.08M | $1.04M | $1.49M |
| Operating Income | $-7.17M | $-10.31M | $-9.32M | $-3.23M | $-1.20M | $-1.63M |
| Operating Margin | N/A | N/A | -3741.48% | N/A | N/A | N/A |
| Net Income | $-7.72M | $-9.95M | $-9.30M | $-3.73M | $-1.13M | $-757.72K |
| Net Margin | N/A | N/A | -3733.11% | N/A | N/A | N/A |
| EPS (Basic) | $-456.76 | $-290.48 | $-292.88 | $-118.68 | $-56.76 | $-38.20 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A |
Company coverage
Latest news
Show 12 more stories
Insider Trading
View AllCompany
About the company
Bluejay Diagnostics, Inc. functions as a company specializing in medical diagnostic solutions. A key offering is their Symphony platform, an advanced technological system. This platform is composed of the Symphony analyzer, which skillfully orchestrates the processing of whole blood, the isolation of biomarkers, and the preparation of immunoassays using non-contact centrifugal force. It also includes the Symphony Cartridge, which comes pre-loaded with essential reagents and components. The company additionally provides the ALLEREYE diagnostic test, a convenient, on-site device for quickly identifying allergic conjunctivitis. Bluejay Diagnostics is also progressing with the development of Symphony IL-6 tests, intended for monitoring disease advancement in critical care environments. Furthermore, they are actively creating additional diagnostic tests for their Symphony platform, such as those aimed at detecting myocardial infarction (heart attack) and congestive heart failure. Bluejay Diagnostics, Inc. was founded in 2015 and is headquartered in Acton, Massachusetts.